EAM
HRTX icon

Eventide Asset Management’s Heron Therapeutics HRTX Stock Holding History

Eventide Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-225,000
Closed -$2.95M – 125
2016
Q4 		$2.95M Buy
+225,000
New +$3.53M 0.19% 85

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Eventide Asset Management's HRTX Position: Q1 2017 in Review

Eventide Asset Management sold out of Heron Therapeutics (HRTX) in Q1 2017, closing a stake of 225,000 shares — an estimated $2.95M sold.

Eventide Asset Management first reported a position in HRTX in Q4 2016 and held it in 1 quarter. The position peaked at $2.95M in Q4 2016. 100 funds tracked by Wall St. Rank hold HRTX as of Q1 2017.

  • Eventide Asset Management reported no remaining Heron Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Eventide Asset Management sold 225,000 Heron Therapeutics shares in Q1 2017, an estimated $2.95M.
  • Eventide Asset Management first reported a position in Heron Therapeutics in Q4 2016 and held it in 1 quarter.
  • Eventide Asset Management's Heron Therapeutics position peaked at $2.95M in Q4 2016.
  • 100 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2017.

Based on Eventide Asset Management's 13F filing for Q1 2017, filed 15 May 2017.